• 1
    Meade TW, North WR, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovie M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; i: 10504.
  • 2
    Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies. JAMA 1998; 279: 147782.
  • 3
    Fibrinogen Studies Collaboration. Collaborative meta-analysis of prospective observational studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Prev Rehabil 2004; 11: 917.
  • 4
    Lowe GDO, Fowkes FGR, Koenig W, Mannucci PM, eds. Fibrinogen and cardiovascular disease. Eur Heart J 1995; 16 (Suppl. A): 163.
  • 5
    Lowe GDO. Haemostatic risk factors for arterial and venous thrombosis. In: PollerL, LudlamCA, eds. Recent Advances in Blood Coagulation, Vol. 7. Edinburgh: Churchill Livingstone, 1997: 6996.
  • 6
    Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 1526.
  • 7
    Koenig W, Rosenson RS. Acute-phase reactants and coronary heart disease. Semin Vasc Med 2002; 4: 41728.
  • 8
    Lowe GDO, Drummond MM, Lorimer AR, Hutton I, Forbes CD, Prentice CRM, Barbenel JC. Relationship between extent of coronary artery disease and blood viscosity. BMJ 1980; i: 6734.
  • 9
    ECAT Angina Pectoris Study Group. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 817.
  • 10
    Lowe GDO, Fowkes FGR, Dawes J, Donnan PT, Lennie SE, Housley E. Blood viscosity, fibrinogen and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993; 87: 1915.
  • 11
    Leng GC, Papacosta O, Whincup P, Wannamethee G, Walker M, Ebrahim S, Nicolaides AN, Dhanjil S, Griffin M, Belcaro G, Rumley A, Lowe GDO. Femoral atherosclerosis in an older British population: prevalence and risk factors. Atherosclerosis 2000; 152: 16774.
  • 12
    Lee AJ, Mowbray PI, Lowe GDO, Rumley A, Fowkes FGR, Allan PL. Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. Circulation 1998; 97: 146773.
  • 13
    Davey-Smith G, Ebrahim S. Mendelian randomisation': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32: 122.
  • 14
    Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol 1990; 43: 91319.
  • 15
    Wannamethee SG, Lowe GDO, Shaper AG, Rumley A, Lennon L, Whincup PH. Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in type 2 diabetes with and without coronary heart disease. Diabetologia 2004; 47: 155765.
  • 16
    Brunner E, Davey-Smith G, Marmot M, Canner R, Beksinska M, O'Brien J. Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen. Lancet 1996; 347: 100813.
  • 17
    Steptoe A, Kunz-Ebrecht S, Owen N, Feldman PJ, Rumley A, Lowe GDO, Marmot M. Influence of socio-economic status and job control on plasma fibrinogen responses to acute mental stress. Psychosom Med 2003; 65: 13744.
  • 18
    Wannamethee SG, Lowe GDO, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002; 105: 178590.
  • 19
    Wannamethee SG, Lowe GDO, Shaper AG, Whincup PH, Rumley A, Walker M, Lennon L. The effects of different alcoholic drinks on lipids, insulin and haemostatic and inflammatory markers in older men. Thromb Haemost 2003; 90: 10807.
  • 20
    Green KG, Heady A, Oliver MF. Blood pressure, cigarette smoking and heart attack in the WHO co-operative trial of clofibrate. Int J Epidemiol 1989; 18: 35560.
  • 21
    Meade T, Zuhrie R, Cook C, Cooper J on behalf of the MRC General Practice Research Framework. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. Br Med J 2002; 325: 113943.
  • 22
    MacCallum PK, Cooper JA, Rumley A, Lowe GDO, Meade TW. Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease. J Thromb Haemost 2004; 2: 3645.
  • 23
    Brull DJ, Dhamrait S, Moulding R, Rumley A, Lowe GDO, World MJ, Humphries SE, Montgomery HE. The effect of fibrinogen genotype on fibrinogen levels after strenuous physical exercise. Thromb Haemost 2002; 87: 3741.
  • 24
    Youngman LD, Keavney BD, Palmer A, Parish S, Clark S, Danesh J, Delepine M, Lathrop M, Peto R, Collins R. Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and in 6002 controls: test of causality by ‘Mendelian randomisation’. Circulation 2000; 102: 312.
  • 25
    Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle aged men and women—the Scottish Heart Health Study. Eur Heart J 1998; 19: 5562.
  • 26
    Lowe GDO, Rumley A, Norrie J, Ford I, Shepherd J, Cobbe S, Macfarlane P, Packard C. on behalf of the West of Scotland Coronary Prevention Group. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost 2000; 84: 5538.
  • 27
    Woodward M, Oliphant J, Lowe GDO, Tunstall-Pedoe H. The contribution of contemporaneous risk factors to social inequality in coronary heart disease and all causes mortality. Prev Med 2003; 36: 5618.
  • 28
    Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs 1997; 54: S3240.
  • 29
    Danesh J, Wheeler JG, Hirshfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GDO, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 138797.
  • 30
    Rumley A, Woodward M, Hoffmeister A, Koenig W, Lowe GDO. Comparison of plasma fibrinogen by Clauss, prothrombin-time derived, and immunonephelometric assays in a general population: implications for risk stratification by thirds of fibrinogen. Blood Coagul Fibrinolysis 2003; 14: 197201.
  • 31
    Rosenson RS, Tangrey CC, Hafner JM. Intra-individual variability of fibrinogen levels and cardiovascular risk profile. Arterioscler Thromb 1994; 14: 192832.